title: Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
abstract: BACKGROUND
  Little is known on factors predicting sunitinib toxicity. Recently, the condition of low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in metastatic renal cell cancer (mRCC) patients treated with sorafenib. We investigated whether sarcopenia could predict early dose-limiting toxicities (DLTs) occurrence in mRCC patients treated with sunitinib.
  
  
  METHODS
  Consecutive mRCC patients treated with sunitinib were retrospectively reviewed. A DLT was defined as any toxicity leading to dose reduction or treatment discontinuation. Body composition was evaluated using CT scan obtained within 1 month before treatment initiation.
  
  
  RESULTS
  Among 61 patients eligible for analysis, 52.5% were sarcopenic and 32.8% had both sarcopenia and a body mass index (BMI)<25 kg m(-2). Eighteen patients (29.5%) experienced a DLT during the first cycle. Sarcopenic patients with a BMI<25 kg m(-2) experienced more DLTs (P=0.01; odds ratio=4.1; 95% CI: (1.3-13.3)), more cumulative grade 2 or 3 toxicities (P=0.008), more grade 3 toxicities (P=0.04) and more acute vascular toxicities (P=0.009).
  
  
  CONCLUSIONS
  Patients with sarcopenia and a BMI<25 kg m(-2) experienced significantly more DLTs during the first cycle of treatment.
authors: Department of Medical Oncology, University Paris Descartes, Paris, France.
authors: O
authors: O
authors: Huillard
authors: O
authors: O
authors: Mir
authors: M
authors: M
authors: Peyromaure
authors: C
authors: C
authors: Tlemsani
authors: J
authors: J
authors: Giroux
authors: P
authors: P
authors: Boudou-Rouquette
authors: S
authors: S
authors: Ropert
authors: N Barry
authors: NB
authors: Delongchamps
authors: M
authors: M
authors: Zerbib
authors: F
authors: F
authors: Goldwasser
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015992:Body Mass Index; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005544:Forecasting; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000009:adverse effects*; D012189:Retrospective Studies; D055948:Sarcopenia / Q000503:physiopathology*; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib